Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

Liminal BioSciences

Status and phase

Terminated

Phase 3

Phase 2

Conditions

Alström Syndrome

Treatments

Drug: PBI-4050

Study type

Interventional

Funder types

Industry

Identifiers

NCT03184584

PBI-4050-CT-9-10

Details and patient eligibility

About

Phase 2, open-label, single-arm, multi-centre study evaluating the long term safety and tolerability of PBI-4050 in subjects with Alström Syndrome who have completed a preceding ProMetic-sponsored Alström Syndrome study with PBI-4050.

Full description

This is a Phase 2, open-label, single-arm, multi-centre study evaluating the long term safety and tolerability of PBI-4050 in subjects with Alström Syndrome who have completed the end-of-treatment (EoT) visit in a preceding ProMetic-sponsored Alström Syndrome study with PBI-4050. This study will also evaluate the efficacy and pharmacological effects of PBI 4050 in this multi faceted disorder. Approximately 20 to 30 subjects will be enrolled to receive 800 mg PBI-4050 once daily for 96 weeks or until product licensing or study termination by the Sponsor, whichever occurs first.

Enrollment

10 patients

Sex

All

Ages

16+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject completed a preceding ProMetic-sponsored Alström syndrome study with PBI-4050.
Subject has signed informed consent
Subject has a documented diagnosis of Alström syndrome
Subject receiving antidiabetic medications is able and willing to self-monitor blood glucose levels
Subject must be willing to forego other forms of experimental drug treatment during the study.
Female subjects of childbearing potential must have a negative serum pregnancy test at screening and agree to use adequate birth control from screening throughout the study and for 30 days after the last Investigational Medicinal Product (IMP) administration
If a male subject has not been vasectomized at least 6 months before screening and partners with a woman of childbearing potential, he must be willing to use an acceptable contraceptive method throughout the study and for 30 days after the last IMP administration.

Exclusion criteria

Subject discontinued PBI-4050 for safety reasons from any preceding ProMetic-sponsored Alström syndrome study with PBI-4050
Subject has had a documented episode of severe hypoglycaemia within 12 months before screening and investigator judges that the subject is unable to adequately monitor their glucose levels.
Subject has uncontrolled hypertension with BP > 170/100 mmHg as determined at screening.
Woman who is pregnant, breast-feeding, or planning a pregnancy during the course of the study as determined at screening
Subject has any condition that, in the investigator's opinion, is likely to interfere with study conduct and compliance
Subject has a history of an allergic reaction to PBI-4050 or any of its excipients.